Paul Shapiro, PhD, and Jeffrey Hasday, MD, are developing a class of drugs that may be able to reset the natural balance of inflammation and prevent a number of serious diseases.

The Mass Spectrometry Center at UMSOP is a collaborative hub where cutting-edge instrumentation and scientific expertise come together to solve complex research challenges and support groundbreaking discoveries across the globe.

Researchers are developing a novel therapy using safe, drug-free nanoparticles to aid the body in fighting sepsis more effectively.

Allan Doctor, MD, of the School of Medicine and Joga Gobburu, PhD, MBA, of the School of Pharmacy are optimistic they are on the cusp of developing the world’s first viable artificial blood.

International relationship focuses on global health education, research, and interprofessional collaboration.

Expansion will enhance public health and communication across Maryland and District of Columbia.

New study sheds light on how disease progression and biomolecular corona affect nanoparticle-mediated immune activation.

Pharmaceutical scientist aims to foster continued collaborations and drive interdisciplinary research.

Read about the groundbreaking new program that is believed to be the first of its kind in the world in the latest issue of “CATALYST.”

Fadia Shaya, PhD, MPH, FAMIA, is one of seven professors from the University of Maryland, Baltimore and the University of Maryland, College Park to receive the honor.

The lead training specialist for The PATIENTS Program is a catalyst for community engagement and innovation.

Congdon is a professor in the Department of Practice, Sciences, and Health Outcomes Research.